Stem Cell Stocks Rise, Led By Athersys Inc. (ATHX, NBS, STEM)

Health and Healthcare

Published: December 21, 2009 2:33 pm

Last Updated: March 10, 2020 6:18 pm

Stem cell stocks (tracked in Tickerspy’s Stem Cell Stock’s Index (*RXSTM) are up over 7% today, led by Athersys Inc (NASDAQ: ATHX). Athersys Inc. rose as high as 395% this morning following news that the company has entered into a deal with Pfizer (NYSE: PFE) to develop Athersys’s MultiStem, an experimental treatment for inflammatory bowel disease. Athersys recieved an intial payment of $6 million in addition to funding for research. Should the program be successful Athersys will recieved as much as $105 million as well as royalties from sales of the drug should it come to mark.

Other stem cell stocks received a big boost from the news. Neostem Inc. (AMEX: NBS), which operates a operates a center for the collection and storage of stem cell, rose as high as 7.6%. StemCells Inc. (NASDAQ: STEM), which attempts to treat organ disorders with stem cells, climbed as high as 7.2%

Garrett W. McIntyre

Are You Ahead, or Behind on Retirement? (sponsor)

If you’re one of the over 4 Million Americans set to retire this year, you may want to pay attention. Many people have worked their whole lives preparing to retire without ever knowing the answer to the most important question: are you ahead, or behind on your retirement goals?

Don’t make the same mistake. It’s an easy question to answer. A quick conversation with a financial advisor can help you unpack your savings, spending, and goals for your money. With SmartAsset’s free tool, you can connect with vetted financial advisors in minutes.

Why wait? Click here to get started today!